Teva Pharmaceutical Industries (TEVA) Other Non-Current Assets (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Other Non-Current Assets for 18 consecutive years, with $1.8 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Assets fell 2.61% year-over-year to $1.8 billion; the trailing twelve-month figure through Jun 2026 stood at $1.8 billion (down 2.61% YoY), and the FY2025 full-year result was $1.8 billion, up 4.01% from the prior year.
• Other Non-Current Assets steadied at $1.8 billion in Q2 2026 per TEVA's latest filing, from $1.8 billion in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $1.8 billion in Q2 2025 and bottomed at $434.0 million in Q2 2024.
• Historically, Other Non-Current Assets has averaged $981.9 million across 5 years, with a median of $471.0 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets decreased 15.44% in 2022, then jumped 324.42% in 2025.
• Over 5 years, Other Non-Current Assets stood at $441.0 million in 2022, then climbed by 6.58% to $470.0 million in 2023, then surged by 276.81% to $1.8 billion in 2024, then grew by 4.01% to $1.8 billion in 2025, then fell by 2.61% to $1.8 billion in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $1.8 billion, $1.8 billion, and $1.8 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.